Transgenomic has appointed Matthew Beer as vice president of business development for oncology; and John McAuliffe as vice president of business development for neurology.

Beer was previously director of oncology marketing and hematology/oncology life cycle leader at Quest Diagnostics. Prior to that, he was vice president of business development at Caris Life Sciences. He has also worked for Abbott, Targeted Molecular Diagnostics, and Oncotech. He holds a BS in microbiology from the University of Iowa.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.